Evidence map›Paper›PMID 41254115›Full record

ArticleLeukemia2026

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Matthew Salmon, Nicole Naumann, Jenny Rinke, Manja Meggendorfer, Deepti Radia, Mark Pomfret, Thomas Ernst, Andreas Hochhaus, Andreas Reiter, William J Tapper and 2 more

Abstract read
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Frontiers in oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew SalmonFaculty of Medicine, University of Southampton, Southampton, UK.
Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Jenny RinkeKlinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0009-0006-7791-6561
Manja MeggendorferMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, Germany.ORCID http://orcid.org/0000-0002-9038-3265
Deepti RadiaDepartment of Clinical Haematology, Guy's and St Thomas' NHS Hospitals, London, UK.
Mark PomfretAll Wales Genomics Laboratory, Cardiff, UK.
Thomas ErnstKlinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-2147-489X
Andreas HochhausKlinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-0626-0834
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
William J TapperFaculty of Medicine, University of Southampton, Southampton, UK.
Helen WhiteFaculty of Medicine, University of Southampton, Southampton, UK.
Nicholas C P CrossFaculty of Medicine, University of Southampton, Southampton, UK. ncpc@soton.ac.uk.ORCID http://orcid.org/0000-0001-5481-2555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diverse haematological neoplasms are driven by tyrosine kinase (TK) fusion genes formed by recurrent or non-recurrent genomic rearrangements. The resulting chimeric proteins often present excellent targets for treatment with kinase inhibitors, and the fusion transcripts or genomic junctions can be used as specific targets for molecular monitoring. Whilst the TK genes involved are generally well characterised (e.g. ABL1, PDGFRA, FGFR1), the fusion partners are very diverse, presenting a challenge for detection and characterisation of these structural variants (SV) using current diagnostic methods. We assessed the ability of targeted nanopore sequencing using adaptive sampling to detect fusion genes in myeloid neoplasms. We sequenced genomic DNA from patients (n = 20) with a known or suspected TK gene fusion and identified rearrangements in 18 cases, including all cases with a known TK fusion, typical and atypical BCR::ABL1 rearrangements, an 843Kb deletion causing a FIP1L1::PDGFRA fusion, novel AGAP2::PDGFRB and NFIA::PDGFRB fusions, and a complex CCDC88C::PDGFRB rearrangement with multiple translocation events. The approach was fast (<72 h/sample from DNA to result), flexible with minimal hands-on laboratory time, and provided accurate, patient-specific characterisation of genomic breakpoints.

Indexed as

Hematologic NeoplasmsNanopore SequencingOncogene Proteins, FusionProtein-Tyrosine KinasesSequence Analysis, DNAAdultFemaleGene RearrangementHumansMaleMiddle AgedOncogene Proteins, FusionProtein-Tyrosine Kinases

Identifiers

PMID41254115
PMCPMC12789007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.